Last reviewed · How we verify
trisodium citrate
Trisodium citrate acts as an anticoagulant by chelating calcium ions, preventing blood clotting in vitro and in extracorporeal circuits.
Trisodium citrate acts as an anticoagulant by chelating calcium ions, preventing blood clotting in vitro and in extracorporeal circuits. Used for Anticoagulation in blood collection tubes and extracorporeal circuits (hemodialysis, apheresis), Oral treatment of metabolic acidosis and prevention of kidney stone formation.
At a glance
| Generic name | trisodium citrate |
|---|---|
| Also known as | regional anticoagulation with citrate, Citralock® |
| Sponsor | Onze Lieve Vrouwe Gasthuis |
| Drug class | Anticoagulant / Alkalinizing agent |
| Target | Ionized calcium (Ca2+) |
| Modality | Small molecule |
| Therapeutic area | Hematology / Nephrology |
| Phase | FDA-approved |
Mechanism of action
Trisodium citrate binds ionized calcium (Ca2+) in blood, reducing the concentration of free calcium below the threshold required for the coagulation cascade to proceed. This makes it useful as an anticoagulant in blood collection tubes, hemodialysis circuits, and other extracorporeal blood handling procedures. It is also used orally as an alkalinizing agent to treat metabolic acidosis and prevent kidney stone formation.
Approved indications
- Anticoagulation in blood collection tubes and extracorporeal circuits (hemodialysis, apheresis)
- Oral treatment of metabolic acidosis and prevention of kidney stone formation
Common side effects
- Hypocalcemia (when used systemically)
- Gastrointestinal upset (oral formulation)
- Hypernatremia (sodium overload)
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (PHASE2)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- trisodium citrate CI brief — competitive landscape report
- trisodium citrate updates RSS · CI watch RSS
- Onze Lieve Vrouwe Gasthuis portfolio CI